These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1778332)

  • 1. Calculation of efficacy of acellular pertussis vaccine from the number of pertussis patients and vaccinees in three areas.
    Ohkuni H; Yabiku M; Togawa M; Fukai K; Yosida I; Minekawa Y; Kitamura T
    Dev Biol Stand; 1991; 73():43-9. PubMed ID: 1778332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of acellular pertussis vaccine in Japan--comparison of two areas, one area where immunization started at 6 months and the other area at over 2 years of age--Regional Surveillance Committee on Tuberculosis and Infectious Diseases of Osaka.
    Ohkuni H; Kitaura T; Tamai T; Takasugi Y; Sugimoto T; Fukai K
    Tokai J Exp Clin Med; 1988; 13 Suppl():51-4. PubMed ID: 3273619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between bacterial meningitis and acellular pertussis vaccine.
    Yabiku M; Ohkuni H; Shiomi M; Ishii T; Shimotuji T
    Dev Biol Stand; 1991; 73():315-21. PubMed ID: 1778325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of the Japanese acellular pertussis vaccine after intrafamiliar exposure to pertussis patients.
    Isomura S; Suzuki S; Sato Y
    Dev Biol Stand; 1985; 61():531-7. PubMed ID: 3914964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical studies on efficacy and safety of an acellular pertussis vaccine in Aichi Prefecture, Japan.
    Isomura S
    Dev Biol Stand; 1991; 73():37-42. PubMed ID: 1778331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
    Gustafsson L; Hessel L; Storsaeter J; Olin P
    Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against pertussis by Takeda's acellular pertussis vaccine: household contact studies in Kawasaki City, Japan.
    Kato T; Kaku H; Arimoto Y
    Tokai J Exp Clin Med; 1988; 13 Suppl():35-8. PubMed ID: 3078808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experiences with acellular pertussis vaccine in Japan and epidemiology of pertussis.
    Kimura M; Kuno-Sakai H
    Tokai J Exp Clin Med; 1987 Dec; 12(5-6):263-73. PubMed ID: 3508651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine.
    Rendi-Wagner P; Kundi M; Mikolasek A; Vécsei A; Frühwirth M; Kollaritsch H
    Vaccine; 2006 Aug; 24(33-34):5960-5. PubMed ID: 16757063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children.
    Vickers D; Ross AG; Mainar-Jaime RC; Neudorf C; Shah S
    CMAJ; 2006 Nov; 175(10):1213-7. PubMed ID: 17098950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results with a new DTP vaccine in Japan.
    Kimura M; Hikino N
    Dev Biol Stand; 1985; 61():545-61. PubMed ID: 2872131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monitoring of a whooping cough epidemic 1994/95 in Switzerland using the sentinel notification system. Sentinella Registry].
    Matter HC; Schmidt-Schläpfer G; Zimmermann H
    Schweiz Med Wochenschr; 1996 Aug; 126(34):1423-32. PubMed ID: 8848704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical studies on efficacy and safety of acellular pertussis vaccine.
    Isomura S
    Tokai J Exp Clin Med; 1988; 13 Suppl():39-43. PubMed ID: 3078809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada.
    Bettinger JA; Halperin SA; De Serres G; Scheifele DW; Tam T
    Pediatr Infect Dis J; 2007 Jan; 26(1):31-5. PubMed ID: 17195702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Swedish efficacy trial of acellular pertussis vaccines--update and time for reflection.
    Olin P
    Dev Biol Stand; 1991; 73():33-6. PubMed ID: 1778327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of vaccination against pertussis on the incidence of pertussis in The Netherlands, 1996-2003].
    de Greeff SC; Schellekens JF; Mooi FR; de Melker HE
    Ned Tijdschr Geneeskd; 2005 Apr; 149(17):937-43. PubMed ID: 15884408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Japanese clinical experiences with acellular pertussis vaccines.
    Kimura M
    Dev Biol Stand; 1991; 73():5-9. PubMed ID: 1778333
    [No Abstract]   [Full Text] [Related]  

  • 19. Experience with diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine in Japan.
    Sato H; Sato Y
    Clin Infect Dis; 1999 Jun; 28 Suppl 2():S124-30. PubMed ID: 10447030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case-control study of vaccination history in relation to pertussis risk during an outbreak among school students.
    Khan FN; Lin M; Hinkle CJ; Franklin P; Luther R; Woodruff F; Henson K; Lukenbill M; Gutierrez M; Zhu BP
    Pediatr Infect Dis J; 2006 Dec; 25(12):1132-6. PubMed ID: 17133158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.